1 Safety and immunogenicity of SW-BIC-213, a modified COVID-19

2 Lipo-Polyplex mRNA vaccine, in Laotian healthy adults aged 18

3 years and above: a Phase 1/2 trial

- 4 Yujie Chen^{1, 8}, Jingxin Li^{2, 8}, Davone Duangdany³, Chanthala Phamisith⁴, Bo Yu¹,
- 5 Shengke Lan¹, Lairun Jin², Dawei Lv¹, Yang Li¹, Bin Luo¹, Peng Han¹, Jinyan Wu¹,
- 6 Yuzhu Wang¹, Congcong Xu¹, Mingyun Shen¹, Fanfan Zhao¹, Peipei Liu⁵, Rongjuan
- 7 Pei⁶, Haifa Shen¹, Wuxiang Guan^{6,9}, Hangwen Li^{1, 9}, Mayfong Mayxay^{7, 9}
- 8

9 Affiliations:

- 10 1. Stemirna Therapeutics, Shanghai, China
- 11 2. Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
- 12 3. Food and Drug Department, Ministry of Health, Vientiane, Laos
- 13 4. Savannakhet Province Hospital, Savannakhet, Laos
- 14 5. Chinese center for disease control and prevention, China
- 15 6. Wuhan Institute of Virology, Wuhan, China
- 16 7. Institute of Research and Education Development, University of Health Sciences,
- 17 Vientiane, Lao People's Democratic Republic
- 18 8. Joint first authors; contributed equally
- 19 9. Joint senior authors; contributed equally

20 **Correspondence to:**

- 21 Wuxiang Guan, guanwx@wh.iov.cn
- 22 Hangwen Li, lihangwen@stemirna.com
- 23 Mayfong Mayxay, mayfong@tropmedres.ac
- 24 Lead contact:
- 25 Hangwen Li, lihangwen@stemirna.com
- 26
- 27
- 28

29 ABSTRACT

Background The mRNA vaccine against SARS-CoV-2 has demonstrated remarkable efficacy in protecting against coronavirus disease 2019 (COVID-19), including providing high protection against severe disease during the emergence of variant waves. In this study, we aimed to investigate the safety and immunogenicity of a 2-dose regimen of the LPP-based mRNA vaccine, SW-BIC-213, in Laos.

35 **Methods** For this phase 1/2 clinical trial, we recruited healthy adults aged 18-60 years (phase 1) 36 or ≥18 years (phase 2) from Mahosot Hospital (Vientiane) and Champhone District Hospital 37 (Savannakhet). Participants with SARS-CoV-2 infection, previous COVID-19 vaccination, known 38 allergies to any vaccine component, or pregnancy were excluded. In the phase 1 trial, 41 eligible 39 participants were sequentially assigned to either the 25 µg dose group (25 µg) or the 45 µg dose 40 group (45 µg) in accordance with their enrollment order, with 21 participants in 45 µg dose group 41 and 20 participants in 25 µg dose group. In the phase 2 trial, 480 participants were randomly 42 allocated (2:2:1 ratio) to either the 25 µg dose group, 45 µg dose group, or placebo group.

- 43 The primary endpoints for the phase 1 trial were the incidence of local/systemic solicited adverse 44 reactions/events (0-6 days after each vaccination dose), unsolicited adverse events (0-21 days and 45 0-28 days after the first and second dose of immunization, respectively), and serious adverse events 46 from the first dose of vaccination to 28 days after completing the full course of immunization. In 47 the phase 2 trial, the primary endpoints were the seroconversion rate and geometric mean titer 48 (GMT) of SARS-CoV-2 S-protein specific IgG antibodies and neutralizing antibodies 14 days 49 after the second dose in participants. As for neutralizing antibodies, we detected pseudo-virus 50 neutralizing antibody against wild type (WT), Delta, BA.1 and BA.2. We also detected live viral 51 neutralizing antibody against WT strain 14 days after the second dose. Furthermore, the safety 52 endpoints were also measured during the trial.
- This seamless phase 1/2 trial was registered with ClinicalTrials.gov under the identifier
 NCT05144139.
- Results Between December 3, 2021, and March 31, 2022, a total of 41 participants were recruited in the phase 1 trial, while the phase 2 trial enrolled 480 participants from January 20 to July 6, 2022. In the phase 1 trial, a total of 32 subjects (80.0%) reported 103 cases of adverse reactions.
- All adverse reactions were limited to Grade 1-2. In the phase 2 trial, a total of 479 subjects, 372

59 subjects (77.7%) reported 929 cases of adverse reactions. All adverse reactions in severity of Grade

- 60 3 were manifested as fever (3.4%, 2.1% and 2.9% in 45 μg dose, 25 μg dose and placebo group
- 61 respectively, only observed in adults), except which all other reactions were limited to Grade 1-2.
- 62 All adverse reactions noted during the study were tolerable, predominantly transient, and resolved
- 63 spontaneously. No serious adverse events (SAEs) related to vaccination were observed.
- 64 In Phase 2 study, SW-BIC-213 could elicit a high level of seroconversion rate of pseudo-virus
- 65 neutralizing antibody against WT (100.0% in 25 µg dose group, 99.3% in 45 µg dose group), Delta
- 66 (99.2% in 25 μg dose group, 98.0% in 45 μg dose group), Omicron BA.1 (84.1% in 25 μg dose
- 67 group, 84.7% in 45 μg dose group) and Omicron BA.2 (96.0% in 25 μg dose group, 88.8% in 45
- 68 µg dose group) at 14 days after the second dose. The pseudo-virus neutralizing antibody titer
- 69 against WT, Delta, BA.1 and BA.2 was all significant higher (P<0.0001) in both 45 μg dose group
- 70 (1175.02, 620.62, 72.39 and 172.80) and 25 µg dose group (885.80, 579.40, 47.24 and 101.96)
- 71 compared with the placebo group (9.67, 10.66, 13.99 and 29.53) at 14 days after the second dose.
- 72 As for live viral neutralizing antibodies against WT strain, the seroconversion rate could reach
- 73 more than 94% at 14 days after second dose. The neutralizing antibody titer against WT strain was
- significantly higher (P<0.0001) in both 45 µg dose group (315.00) and 25 µg dose group (323.18)
- compared with the placebo group (8.51) at 14 days after second dose.
- 76 Conclusion: COVID-19 mRNA vaccine SW-BIC-213 manifests a favorable safety profile and is
- highly immunogenic in eligible subjects aged ≥ 18 years.
- 78 Keywords: SARS-CoV-2, mRNA vaccine, SW-BIC-213, LPP, Clinical trial, Laos
- 79

INTRODUCTION 80

81 Since the emergence of COVID-19, it has had a huge impact on the whole world¹. According to 82 statistics from the World Health Organization (WHO), there has been over 767 million confirmed cases of COVID-19, including 6.9 million deaths as of June 2023². One of the best ways to prevent 83

84 and slow down the transmission is vaccination³.

85 In response to the COVID-19 outbreak caused by the SARS-CoV-2 virus, numerous of vaccines

86 development programs have been launched. As of March 2023, the World Health Organization's 87

88 utilize various platforms, including live attenuated vaccines, recombinant protein vaccines, vector

vaccine tracker reported a total of 382 vaccine candidates under development⁴. These candidates

89 vaccines (replication-incompetent vector vaccines, replication-competent vector vaccines, and

- inactivated virus vector vaccines), DNA vaccines and RNA vaccines⁵⁻¹⁰. Among these platforms, 90
- 91 mRNA vaccines have demonstrated the highest protective efficacy⁵⁻⁷. Notably, BNT162b2 and

92 mRNA-1273 are representative mRNA vaccines against SARS-CoV-2. The BNT162b2 vaccine,

93 administered as a two-dose regimen (30 μ g per dose, with a 21-day interval), has shown a safety

profile and 95% efficacy against COVID-19¹¹. Similarly, the mRNA-1273 vaccine exhibited 94.1% 94

95 efficacy in preventing COVID-19 illness, including severe disease¹². These vaccines have made

96 significant contributions in controlling the COVID-19 pandemic and have demonstrated the

97 feasibility of mRNA vaccine technology.

98 SW-BIC-213 is an investigational mRNA that encodes a modified full-length spike protein of WT 99 SARS-CoV-2, incorporating mutations such as 2P mutation, furin mutation, and D614G mutation¹³. It is based on Lipo-Polyplex (LPP) platform¹⁴. In this study, we present the clinical 100 101 trial data from a Phase 1/2 trial among healthy volunteers in Laos (Lao PDR) to assess the safety 102 and immunogenicity of the LPP-based mRNA vaccine against COVID-19.

103

- 105
- 106

107 **METHODS**

108 Study design and participants

We conducted a seamless Phase 1/2 study in Laos to evaluate the safety and immunogenicity of the COVID-19 mRNA vaccine. The Phase 1 trial employed an open-label, single-arm, dosageescalating design and included healthy individuals aged 18-60 years. The Phase 2 trial utilized a randomized, double-blind, placebo-controlled design and enrolled healthy individuals aged 18 years and above.

114 During the screening visit, participants underwent a medical history review and physical 115examination to ensure overall good health. Both male and female participants of childbearing age 116 agreed to use contraception throughout the trial, and pregnant individuals were excluded. 117Exclusion criteria included a history of SARS/MERS or SARS-CoV-2 infection, experiencing 118 common clinical features of COVID-19 within 14 days prior to enrollment, allergies to vaccine 119 components, history of seizures or mental illness, acute or chronic diseases in the acute phase, 120 congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, or other 121 autoimmune diseases, receipt of blood products within the past 3 months, receipt of other study 122 drugs within the past 6 months, or receipt of any COVID-19 vaccine. The exclusion of 123SARS/MERS or SARS-CoV-2 infection was achieved by asking about infection history and 124 detecting IgG level (2019-nCoV IgG/IgM Detection Kit, Vazyme). Prior to participation, all 125 individuals received comprehensive information about the trial procedures and potential risks and 126 provided their written informed consent.

The trial received approval from the Ethics Committee and Food & Drug Department of the Ministry of Health, Lao PDR (7745). The protocol and each amendment underwent review by the Independent Ethics Committee of the Lao People's Democratic Republic Ministry of Health National Ethics Committee for Health Research. The study adhered to the principles outlined in the Declaration of Helsinki and Good Clinical Practice Guidelines. Safety assessment, including the necessity of study suspension or termination, was conducted by an independent Data Safety Monitoring Board (DSMB).

134 The trial was registered with the identifier NCT05144139 on ClinicalTrials.gov.

- 135
- 136

137

138 **Randomization and blinding**

139In the Phase 1 trial (open-label), eligible participants were assigned in a 1:1 ratio to receive either 140 a 25 µg dose or a 45 µg dose of SW-BIC-213 based on their enrollment sequence. The trial was 141 carried out step by step from the 25 µg dose group to the 45 µg dose group, the 45 µg dose group 142 was enrolled only when the preliminary 7-day safety assessment of the 25 µg dose group was 143 favorable. The Phase 2 trial (blinded) included two age cohorts: the adult group (≥ 18 to ≤ 60 years 144 old) and the seniors group (>60 years old), with a ratio of 3:1. Within each age group, participants 145 were randomized in a 1:1:1 ratio to receive either a 25 µg dose of SW-BIC-213, a 45 µg dose of 146 SW-BIC-213, or a placebo. The randomization of participants into vaccine groups was performed 147 using an interactive response technology (IRT) system. The blocked randomization list was 148 generated by an independent statistician utilizing the SAS system (version 9.4 or later). The staff 149 responsible for vaccine receiving, storing, dispensing, and preparation, who were unblinded, had 150 no further involvement in the trial and were strictly prohibited from disclosing any information 151that could compromise blinding. Throughout the trial, all other investigators, participants, 152laboratory staff, and the sponsor remained blinded.

153 **Procedures**

154 The SW-BIC-213 vaccine was composed of an mRNA encoding full-length spike glycoprotein of 155the Wuhan-HU-1 isolate of SARS-CoV-2. This mRNA included artificial mutations, such as the 156 K986P/V987P (pre-fusion structure) mutation, the 682-QSAQ-685 mutation (substitution of Furin 157cleavage site), and the D614G mutation. This vaccine was formulated with lipo-polyplex and was 158developed and manufactured by StemiRNA Therapeutics Co., Ltd, in Shanghai, China, in 159 accordance with good manufacturing practice guidelines. The vaccine was supplied as a buffered-160 liquid solution in vials, with each vial containing 50 µg of the vaccine in 0.5 mL. It was stored at 161 temperatures ranging from -25°C to -15°C until use. The placebo consisted of a commercial, pre-162 packaged preservative-free saline solution containing 0.9% NaCl.

Each participant received two doses of the SW-BIC-213 vaccine candidate, each dose was 25 μg
or 45 μg or placebo. The vaccinations were administered in the upper arm deltoid muscle, with an
interval of 21 days between each dose. Following each dose, participants were observed on-site
for 30 minutes, during which any adverse reactions were recorded by the investigators. Participants
documented their body temperature and any adverse events on daily cards during the first 7 days

168 after each vaccination. Participants reported any adverse events occurring within 7-21 and 7-28 169 days after the first and second vaccination, respectively, using contact cards. Any serious adverse 170events or pregnancies that developed from the first vaccination until the end of the study were 171monitored, and follow-up was ongoing. In Phase 1 only, participants underwent blood and urine 172sample collection before and 4 days after each dose for hematology and chemistry laboratory tests 173to assess any toxicity following vaccination. The enrollment of each dosage group in the Phase 2 174study was carried out only if the corresponding dosage group in the Phase 1 study demonstrated a 175favorable safety profile.

176Solicited local adverse events at the injection site within 7 days after vaccination included pain, 177pruritus, induration, swelling, redness. Solicited systemic adverse events within 7 days after 178vaccination included fever, fatigue, headache, myalgia, chills, arthralgia, nausea, swollen lymph 179 nodes (lymphadenopathy), diarrhea, vomiting and acute allergic reaction. Unsolicited adverse 180 events occurring within 0-21 days and 0-28 days after the first and second dose respectively were 181 collexted. Unsolicited adverse events were adverse events that were not included in the protocol-182 defined solicited adverse reactions. The severity of adverse events were assessed according to 183 Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events $(Version 2.1)^{15}$. The severity of abnormality in vital sign and laboratory test were primarily 184 185 evaluated using the Guidelines for Adverse Event Classification Standards for Clinical Trials of Preventive Vaccines issued by NMPA (National Medical Products Administration) in 2019¹⁶, and 186 187 further complemented by Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials issued by the FDA in 2007¹⁷. The causal association 188 189 between adverse events and vaccination was final determined by experienced doctors based on 190 actual situation.

191 Blood samples were collected from participants before each dose of vaccination and 14, 90, and 192 180 days after the second dose. These samples were used to evaluate antibody responses, 193 specifically Spike/RBD-specific IgG antibodies and neutralizing antibodies against SARS-CoV-2. 194 The titer of total anti-SARS-CoV-2 spike IgG antibodies were determined using an indirect ELISA 195 assay. ELISA plates were coated with recombinant SARS-CoV-2 spike protein. Plates were 196 washed with PBS-T (phosphate buffered saline (PBS) with 0.05% Tween-20) and blocked with 2% 197 goat serum in PBS-T. Serially diluted standard antibody to SARS-CoV-2 spike protein and heat-198 inactivated human serum samples at a certain dilution were added into wells in duplicate. The

199 bound antigen-antibody complex was detected using a rabbit anti-human IgG horseradish 200 peroxidase (HRP) conjugate, and color development occurred upon the addition of 3.3' 5.5'-201 tetramethylbenzidine (TMB) chromogenic substrate. The absorbance was measured using a 202 microplate reader at 450/630 nm. The titer of IgG in serum samples was quantified using a 203 calibration curve and expressed as RU/mL, which was later converted to WHO International 204 Standard titer (NIBSC CODE: 20/136) as binding antibody units per mL (BAU/mL). Additionally, 205 RBD-specific IgG antibodies were detected using a commercial kit from Vazyme (Nanjing, China) 206 using a similar method. The detection range of binding antibody is 20-800 BAU/ml.

207 The neutralizing antibody titer was determined by a vesicular stomatitis virus (VSV)-based 208 pseudo-virus neutralization assay using commercial kits (Zhongxingrongchuang biotech, Beijing, 209 China). The SARS-CoV-2 pseudo-viruses express full-length spike proteins (Prototype/ Delta/ 210 Omicron BA.1/ Omicron BA.2) and containing a firefly luciferase reporter gene for quantitative 211 measurements of infection by relative light units (RLU). Briefly, SARS-CoV-2 pseudo-virus was 212 preincubated with three-fold serially diluted heat-inactivated human serum samples for 1 hour at 213 37 °C. The medium was also mixed with pseudo-virus as virus control. Then, Vero cells were 214 inoculated with the respective mixtures in 96-well plates. After incubation for 24h at 37 °C, the 215cells were lysed, and luciferase activity was measured using a commercial substrate according to 216 the manufacturer's protocol (Vazyme, Nanjing, China). Luminescence intensity was measured 217 using a microplate reader. The neutralization titer was defined as the reciprocal serum dilution 218 necessary for 50% inhibition of luciferase activity compared with the virus control wells, 219 calculated using the Reed-Muench method. The cut-off value of WT, Delta, BA.1, BA.2 pseudo-220 virus neutralizing antibody is 8, 8, 5, 6, respectively.

Neutralizing antibody titers were determined using a micro-neutralization assay conducted in a biosafety level III laboratory. Serum samples were serially diluted and then incubated at 37°C for one hour with 100 TCID50 doses of the live SARS-CoV-2 WT strain. The serum-virus mixture was then added to Vero cells and incubated for four days. Cytopathic effects (CPE) were observed under electron microscopy, and the serum dilution factor that resulted in 50% CPE was recorded as the neutralizing antibody titer. The cut-off value of neutralizing antibody in phase 1 trial is 2. The detection rage of neutralizing antibody is 10-4426 in phase 2 trial.

- 228
- 229

230 Outcomes

In the phase 1 trial, the primary outcome focused on the safety of COVID-19 mRNA vaccine in healthy people aged 18-60 years. The secondary outcome assessed the humoral immunogenicity and long-term safety for six months. In the phase 2 trial, the primary outcome aimed to evaluate the humoral immunogenicity and safety in healthy people aged 18 years and above. The secondary outcome examined the long-term safety and persistence of humoral immunity for six months.

200 outcome chammed are fong term surely and persistence of numeral minimum persistence of manoral minimum persistence of minimum persistence of manoral minimum persistence of minim

236 Safety outcomes included the incidence of local/systemic solicited adverse reactions/events (0-6

days after each vaccination dose), unsolicited adverse events (0-21 days and 0-28 days after the
first and second dose of immunization, respectively), and serious adverse events from the first dose
of vaccination to 28 days after completing the full course of immunization.

Outcomes for immunogenicity included seroconversion rate and GMT of SARS-COV-2 spike protein specific IgG antibody and neutralizing antibody (Pseudo-virus neutralizing antibody targeting WT, Delta, Omicron BA.1 and Omicron BA.2 14 days after the second dose; live viral neutralizing antibody against WT strain) 14 days after the second dose. In addition, RBD specific IgG antibody was investigated in phase 1 trial as an exploratory endpoint.

245 Statistical analysis

246 The safety analysis included all participants who received at least one dose of the investigational 247 vaccine. Immunogenicity analyses were primarily based on the per protocol set (PPS) and 248 supplemented by the full analysis set (FAS) at various time points, as defined in the study protocol. 249 The full analysis set comprised all subjects who received at least one dose of vaccination and had 250 valid pre-vaccination antibody results. Moreover, the Per protocol set referred to participants who 251were enrolled, following the inclusion and exclusion criteria, completed the vaccination course as 252 protocol defined in the protocol, and had valid pre-vaccination and post-vaccination 253 immunogenicity data. Safety endpoints were presented as percentage of participants experiencing 254 adverse events or serious adverse events during the observation period. To compare the differences 255in proportions across the groups, Fisher's exact test was used. Immunological analysis for IgG and 256 neutralizing antibodies included seroconversion rates and GMT at specified time points. We 257 calculated 95% confidence intervals using the Clopper-Pearson method. Chi-square test/Fisher's 258exact test was used to compare differences in seroconversion rates among the groups. We 259 performed a t-test after log-transformation to compare differences in GMT between the groups. 260 All statistical analyses were conducted using SAS version 9.4.

261	In phase 1 trial, the probability to observe a particular adverse event with an incidence of 8% at
262	least once in 20 participants in each dose group was 81.1%. The actual enrolled sample size was
263	41. For phase 2, the sample size calculation was based on the assumption that the seroconversion
264	rate of vaccine and placebo groups be 80% and 10%, respectively, and the test level would be a
265	unilateral α =0.025. We calculated that, with a sample size of 144 subjects in each vaccine group
266	and 36 subjects in each placebo group for adults and 48 subjects in each vaccine group and 12
267	subjects in each placebo group for seniors, the difference between the vaccine and placebo could
268	be estimated with at least 99% confidence including the consideration of 33% dropout rate. The
269	actual enrolled sample size was 480.
270	
271	
272	
273	
274	
275	
276	
277	
278	
279	
280	
281	
282	
283	
284	
285	
286	
287	
288	
289 200	
290 201	
291	

292 **RESULTS**

293 Patient characteristics

294 Between December 3, 2021, and March 31, 2022, a total of 94 individuals underwent recruitment 295 and screening for Phase 1 trial in Vientiane and Savannakhet, Laos (Fig. 1A). After excluding 53 296 individuals, 41 eligible participants were assigned to two groups, receiving either the 25 µg dose 297 (n=20) or the 45 µg dose (n=21) of the vaccine. Among them, 40 participants (20 in the 45 µg dose 298 group and 20 in the 25 µg dose group) received their first vaccination, and 39 participants (19 in 299 the 45 µg dose group and 20 in the 25 µg dose group) completed the two-dose immunization. The 300 mean age in the 25 μ g dose group was 31.3 years, and in the 45 μ g dose group was 30.2 years, 301 with a balanced age distribution between the two vaccination groups (Table 1).

302 Between January 20, 2022, and July 6, 2022, a total of 863 individuals underwent recruitment and 303 screening for Phase 2 trial in Vientiane and Savannakhet, Laos (Fig. 1B). After excluding 383 304 individuals, 480 eligible participants were randomly assigned to three groups, receiving either the 305 25 μ g dose (n=192) or the 45 μ g dose (n=192) of the vaccine, or placebo (n=96). The mean ages 306 for the placebo group, 25 μ g dose group, and 45 μ g dose group were 46.3 years, 47.5 years, and 307 47.3 years, respectively, with a balanced age distribution among the vaccination groups (Table 1). 308 In the Phase 2 study, a total of 479 eligible subjects received their first vaccination on the deltoid 309 muscle, with the investigational vaccine dosage of 25 μ g or 45 μ g, or placebo. Of them, 376 310 received the second vaccination using the same immune route and dosage as the first vaccination.

311 Safety

312 The Phase 1 study revealed common adverse reactions, including systemic diseases and various 313 local reactions at the site of administration, such as pain (80.0% in 45 µg dose group and 50.0% in 31425 µg dose group), fever (25.0% in 45 µg dose group and 30.0% in 25 µg dose group), fatigue 315 (30.0% in 45 µg dose group and 15.0% in 25 µg dose group), swelling (10.0% in 45 µg dose group 316 and 5.0% in 25 μ g dose group), and headache (35.0% in 45 μ g dose group and 5.0% in 25 μ g dose 317 group). These reactions were limited to grade 1 or 2, with only the occurrence of headache showing 318 a significant difference between the 25 µg dose group and 45 µg dose group (P=0.0436) (Fig. 2A). 319 Nonetheless, all adverse symptoms resolved, mostly spontaneously, and their severity remained 320 limited to Grade 1-2. No grade \geq 3 adverse reactions were reported until the data cutoff date.

321 Similarly, in the Phase 2 study, common adverse reactions were pain (72.4%, 70.8% and 35.7%) 322 for 45 µg dose, 25 µg dose and placebo group, respectively, in adults; 93.8%, 72.9% and 16.7% 323 for 45 µg dose, 25 µg dose and placebo group, respectively, in seniors) at the injection site, fever 324 (37.9%, 36.8% and 35.7% in adults; 33.3%, 33.3% and 12.5% in seniors), fatigue (3.4%, 16.0% 325 and 5.7% in adults; 14.6%, 4.2% and 4.2% in seniors), headache (9.7%, 16.7% and 21.4% in adults; 326 12.5%, 10.4% and 16.7% in seniors), with primarily grade 1 or 2 intensity. Grade ≥ 3 adverse 327 reaction was only observed in fever and in adults, the incidence was merely 3.4%, 2.1% and 2.9% 328 in 45 μ g dose, 25 μ g dose and placebo group respectively. Notably, in the adults group and seniors 329 group, the incidence of pain at the injection site was significantly higher (P<0.0001) in the vaccine 330 group (72.4% and 93.8% for 45 µg dose group, 70.8% and 72.9% for 25 µg dose group) compared 331 to the placebo group (35.7% and 16.7%). Moreover, in the adult group, the incidence of fatigue 332 was significantly higher in the 25 μ g dose group compared to the placebo group (P=0.0005) (Fig. 333 2B). Other adverse effects did not show statistically significant differences between the 45 μ g dose 334 group and 25 μ g dose group. As with Phase 1, all adverse symptoms resolved, with most of them 335 being transient and self-recovering.

In conclusion, the COVID-19 mRNA vaccine, SW-BIC-213, demonstrated a favorable safety profile and was well tolerated by eligible subjects aged ≥ 18 years, regardless of the dose and study phase. Local reactions were more prevalent than systemic reactions among all participants. The adverse reactions observed during the trial were generally tolerable, transient, and self-resolving. All grade 3 adverse reactions were characterized as grade 3 fever and were successfully treated.

341 Immunogenicity assessments

342 In the Phase 1 trial, we assessed antibody responses by measuring participants' serological spike-343 binding IgG titer using ELISA. Comparing data from each vaccination, the post-vaccination GMT 344 in both groups showed an ascending trend from baseline to 21 days after the first dose, and further 345 increased by 14 days after the second dose (Fig. 3A). In 45 µg dose group, GMT increased from 346 12.82 BAU/ml at baseline, through 306.70 after receiving the first dose, to 1853.40 BAU/ml after 347 receiving the second dose. In 25 µg dose group, GMT increased from 11.46 BAU/ml at baseline, 348 through 275.71 BAU/ml after receiving the first dose, to 924.17 BAU/ml after receiving the second 349 dose (Fig. 3A). Although the GMT of the 45 μ g dose group was higher than that of the 25 μ g dose 350 group 14 days after the second dose, no statistically significant difference was observed (P=0.0531) 351 (Fig. 3A). The seroconversion rate of S-protein antibody after the first vaccination was 100.0% in

both the 45 μ g dose group and 25 μ g dose group, while after the second vaccination, it was 100.0% in the 45 μ g dose group and 94.7% in the 25 μ g dose group (Fig. 3B). No significant differences were found between the groups (P = 1.0000). Additionally, both the 45 μ g dose group and 25 μ g dose group exhibited 100.0% seroconversion rates for S-protein specific antibody at both 90 days

- and 180 days after full immunization (Fig. 3B).
- 357 Given the importance of the RBD domain of the S protein for viral entry, antibodies targeting this 358 domain of SARS-CoV-2 were expected to be neutralizing and potentially protective. Therefore, 359 we also measured RBD-binding IgG antibodies using ELISA. Similar to the spike-binding IgG 360 antibodies, GMT post-vaccination in both groups showed an ascending trend from baseline 361 through 21 days after the first dose to 14 days after the second dose (Supplementary Fig. 1A). In 362 45 µg dose group, GMT increased from 12.34 BAU/ml at baseline, through 138.06 BAU/ml after 363 receiving the first dose, to 1988.90 BAU/ml after receiving the second dose. In 25 µg dose group, 364 GMT increased from 10.46 BAU/ml, through 154.79 BAU/ml after receiving the first dose, to 365 1127.61 BAU/ml after receiving the second dose (Supplementary Fig. 1A). After completing full 366 immunization, the GMT in the 45 μ g dose group was higher than that in the 25 μ g dose group, but 367 no significant differences were observed between the groups (P = 1.0000). The seroconversion 368 rate of S-protein antibody after the first vaccination was 94.7% in the 45 µg dose group and 100.0% 369 in the 25 μ g dose group, while after the second vaccination, it was 100.0% in the 45 μ g dose group 370 and 94.7% in the 25 µg dose group (Supplementary Fig. 1B). Seroconversion rates of RBD 371 combining antibody in both the 45 µg dose group and 25 µg dose group remained at 100.0% at 372 both 90 days and 180 days after full immunization (Supplementary Fig. 1B), with no significant 373 differences between the groups (P = 1.0000).

374 In the Phase 2 trial, adults and seniors in the 45 µg dose group and 25 µg dose group showed an 375 increasing trend in GMT of S-protein specific antibody from baseline through 21 days after the 376 first dose to 14 days after the second dose (Fig. 3C). Among younger subjects, the GMT of S-377 protein specific antibody was significantly higher in the experimental group compared to the 378 placebo group after each dose, especially detected at 14 days after the second dose (2051.94 379 BAU/mL, 1853.02 BAU/mL and 20.52 BAU/mL in 45 µg dose group, 25 µg dose group and 380 placebo group, respectively, P<0.0001) (Fig. 3C). However, no significant difference (P=0.1307) 381 was observed between the 45 µg dose group and 25 µg dose group 14 days after the second dose

382 (Fig. 3C). Among seniors group, the GMT of S-protein specific antibody was significantly higher

383 in the experimental group compared to the placebo group after each dose, detected at 14 days after 384 the second dose (3455.81 BAU/mL, 1471.12 BAU/mL and 16.26 BAU/mL in 45 ug dose group, 385 25 µg dose group and placebo group, respectively, P<0.0001), with the 45 µg dose group 386 demonstrating notably higher GMT compared to the 25 µg dose group (P<0.0001) (Fig. 3C). 387 Among younger subjects who received the experimental vaccine, the first dose of vaccination (98.1% 388 for 45 µg dose group, 100% for 25 µg dose group) induced a comparable seroconversion rate to 389 that after the second dose (99.0% in 45 µg dose group, 100% in 25 µg dose group) (Fig. 3D). The 390 seroconversion rate induced by the experimental vaccine was significantly higher than that elicited 391 by the placebo (19.4%) at 14 days after the second dose (P < 0.0001), but there was no significant 392 difference (P=1.0000) between the 45 µg dose group (99.3%) and 25 µg dose group (100.0%). 393 When comparing between age cohorts, the seroconversion rates after full immunization in both 394 cohorts were generally balanced, with both reaching higher than or equal to 99.0%. At 90 days and 395 180 days after full immunization, the seroconversion rates of S-protein specific antibody in both 396 the 45 µg dose group and 25 µg dose group in each age cohort remained at a level of \geq 97% (Fig. 397 3D).

398 The serum samples of participants were also assessed for pseudo-virus neutralizing titers against 399 SARS-CoV-2 prototype strain and three variants of concern (VOC) strains (Delta, Omicron BA.1, 400 and Omicron BA.2). In the Phase 1 trial, the GMT of pseudo-virus neutralizing antibody against 401 WT and Delta strain reached 990.50 and 642.08 in 45 μ g dose group at 14 days after the second 402 dose, 507.17 and 352.98 in 25 µg dose group respectively (Fig. 4A, B). As for BA.1 and BA.2, the 403 GMT at 14 days after the second dose was relatively lower, which was 35.27 and 55.88 in $45 \,\mu g$ 404 dose group, 25.12 and 36.27 in 25 µg dose group (Fig. 4C, D). After receiving two doses of 405 vaccination, the GMTs for all strains in the 45 μ g dose group were consistently higher than that in 406 the 25 µg dose group, but there was no significant difference (P>0.05). At 14 days after full 407 immunization, in the 45 μ g dose group, the seroconversion rate of neutralizing antibodies against 408 WT, Delta, BA.1, and BA.2 were 100.0%, 100.0%, 82.4%, and 82.4%, respectively 409 (Supplementary Fig. 2A, B, C, D). In the 25 µg dose group, these rates were 94.7%, 94.7%, 84.2%, 410 and 47.4%, respectively (Supplementary Fig. 2 A, B, C, D). Except for BA.2 (P=0.0291), 411 seroconversion rates for other strains were balanced between groups (P>0.05) (Supplementary Fig. 412 2A, B, C, D). The GMT of neutralizing antibodies against each strain in each group declined from 413 90 days to 180 days after the second dose, except for neutralizing antibody against Omicron BA.1

414 in the 25 µg dose group, which slightly rose during this period (Fig. 4A, B, C, D). This trend was 415 in line with the seroconversion rate analysis, suggesting that it might be attributed to the activation 416 of immune memory cells by exposure to the pathogen or the hybrid immunity induced by infection. 417 In the Phase 2 trial, the vaccine group showed a significant increase in pseudo-virus neutralizing 418 antibodies against WT, Delta, BA.1, and BA.2 compared to the placebo group (Fig. 4E, F, G, H). 419 At 14 days after the second dose, the GMTs of antibodies against each strain in the 45 μ g dose 420 group (1078.75, 568.87, 70.30 and 146.37 for WT, Delta, BA.1 and BA.2, respectively, in adults; 421 1417.10, 751.08, 77.20 and 248.63 for WT, Delta, BA.1 and BA.2, respectively, in seniors) were 422 generally higher or equal to that in the 25 μ g dose group (825.85, 576.59, 45.51 and 91.11 for WT, 423 Delta, BA.1 and BA.2, respectively, in adults; 1088.26, 587.73, 52.71 and 141.88 for WT, Delta, 424 BA.1 and BA.2, respectively, in seniors). Particularly for neutralizing antibody against Omicron 425 BA.1 (P=0.0262) and Omicron BA.2 (P=0.0399) in the younger cohort, the 45 μ g dose group 426 displayed a significantly higher response (Fig. 4E, F, G, H). The vaccine could elicit relatively 427 higher or generally balanced GMT in seniors (Fig. 4E, F, G, H), which demonstrated that this 428 vaccine was efficient in seniors group. The seroconversion rate of antibodies 14 days after the 429 second dose against each strain were balanced without significant distinction among senior 430 subjects, between the 45 μ g dose group (100.0%, 97.9%, 74.5% and 85.1 for WT, Delta, BA.1 and 431 BA.2, respectively) and 25 µg dose group (100.0%, 100.0%, 81.3% and 93.8 for WT, Delta, BA.1 432 and BA.2, respectively) (Supplementary Fig. 2 E, F, G, H). However, among the younger cohort, 433 the seroconversion rate of BA.2 antibodies was remarkably higher in the 25 µg dose group than 434 that in the 45 μ g dose group (96.8% vs. 89.3%) (Supplementary Fig. 2H), and the seroconversion 435 rate of WT (100.0% vs 99.0%), Dleta (98.9% vs 98.1%), BA.1 (85.1.0% vs 89.3%) was generally 436 balanced (Supplementary Fig. 2 E, F, G). There was no obvious decline in seroconversion rates of 437 each strain from 90 days to 180 days after full immunization for both age cohorts in either the 45 438 µg dose or 25 µg dose group. The slight increase in the seroconversion rate at certain time points 439 might be attributed to changes in the number of participants or infection during the epidemic.

In the phase 1 trial, at 14 days after the second dose, the GMT of WT neutralizing antibody was 302.57 in the 45 μ g dose group and 161.34 in the 25 μ g dose group (Fig. 5A). The seroconversion rates of WT neutralizing antibody were 94.4% in the 45 μ g dose group and 100.0% in the 25 μ g dose group at 14 days after full immunization (Fig. 5B). There was no significant difference between the 25 μ g dose group and the 45 μ g dose group (P=0.4737). In the phase 2 trial, when

445 comparing between the adult cohort and senior cohort, the GMT of neutralizing antibody against 446 WT 14 days after full immunization were 270.81 vs. 438.68 in the 45 µg dose group, 352.83 vs. 447 249.71 in the 25 µg dose group, and 9.44 vs. 6.51 in the placebo group, respectively (Fig. 5C). In 448 all age groups, neutralizing antibody levels were significantly higher in both the 45 μ g dose group 449 and 25 µg dose group compared with the placebo group (P<0.0001). Among adults, there was no 450 significant difference between the 45 μ g dose group and 25 μ g dose group (P=0.0809). However, 451 in the senior group, the neutralizing antibody titer in the 45 µg dose group was significantly higher 452 than that in the 25 μ g dose group (P=0.0264). At 14 days post second dose, the seroconversion 453 rates among adult subjects were similar to that among senior subjects. The seroconversion rates 454 were 97.1% vs. 97.9% in the 45 µg dose group, 97.9% vs. 96.9% in the 25 µg dose group, and 455 21.2% vs. 10.0% in the placebo group (Fig. 5D). Among the age groups, there was a significant 456 difference in the seroconversion rates between the vaccine group and the placebo group 457 (P<0.0001), while there was no significant difference in the seroconversion rates between the 45 458 μ g dose group and the 25 μ g dose group (P=0.8442).

459 **Discussion**

460 In both phase 1 and phase 2 trials, we observed that two-dose SW-BIC-213 with the 25 or 45 μ g 461 doses was well tolerated, with all adverse reactions mainly being transient and could resolved 462 spontaneously. Notably, no of vaccination-related SAE or adverse events of special interest, like 463 ADE/VED, was noticed since the first dose. Adverse reactions in both phase 1 and phase 2 were 464 primarily manifested as local solicited reactions, with the most common symptoms being injection-465 site pain. Importantly, the frequency of solicited systemic adverse reactions events between the 466 vaccine and placebo groups was similar in phase 2. Only a few adults in both the vaccine and 467 placebo groups experienced grade ≥ 3 adverse reactions in phase 2, notably fever. Other reactions 468 were generally limited to Grade 1-2. Overall, SW-BIC-213 showed favorable safe profile with 469 generally mild or moderate reactogenicity, comparable to two well-known mRNA vaccine, mRNA-1273^{18,19} and BNT162b2^{20,21}. 470

471 Humoral responses have been considered as immune correlates of protection against SARS-CoV-

472 2^{22} . SW-BIC-213 exhibited high immunogenicity and induced robust humoral responses rapidly.

473 Specifically, for S-protein IgG antibody, one dose of vaccination could induce comparable

474 seroconversion rate to that achieved after full immunization, which was roughly equal between 45 475 µg dose and 25 µg dose group. In contrast, the seroconversion rate of pseudo-virus neutralizing 476 antibody showed an increasing tendency with the progression of the vaccination regimen, reaching 477 higher levels after completing full immunization, regardless of dosage. As for GMT analysis, both 478 IgG and neutralizing antibodies were induced in a dose-dependent manner. Furthermore, as new 479 variants continue to emerge and cause devastation, the neutralizing antibodies against multiple 480 VOC strains were also evaluated. Our candidate was similar potent against Delta strain compared 481 to WT strain with both high seroconversion rate (>97%) and GMT. Meanwhile, in line with 482 previous results²³⁻²⁷, a remarkable reduction of neutralizing antibodies was found against the 483 Omicron variants, though the seroconversion rate was high to approximate 80% and 96% for 484 Omicron BA.1 and BA.2 respectively at 14 days post full vaccination. For participants aged 60 485 years and older, especially with pre-existing respiratory or cardiovascular disease, COVID-19 presents a remarkably high risk of severe disease and death²⁸. Notably, in this study, the magnitude 486 487 of humoral immunogenicity in the group aged above 60 years was comparable to that of in the 488 group aged 18–60 years in the context of similar safety profile.

489 The long-term tolerability profile of SW-BIC-213 and persistence of the elicited immune 490 responses were also investigated according to the study protocol. Indicated with phase 1 and phase 491 2 trial result, seroconversion rate of WT neutralizing antibody, Delta neutralizing antibody and S-492 protein specific antibody could remain at a relatively high level when coming to 90 days and 180 493 days after full immunization. Situation that seroconversion rate of Omicron BA.1 and Omicron 494 BA.2 neutralizing antibody slightly increased from 90 days to 180 days after full immunization 495 and situation that seroconversion rate of placebo group could reach 50% suggests that there might 496 have been exposure to pathogens or infections during the course of trial and leading to increased 497 antibody levels in individual subjects. Since there was large epidemic in Laos during the trial, this 498 was likely to occur across the groups and did not affect the key conclusion of the comparison 499 between groups. As SARS-CoV-2 continues to evolve and vaccination induced protective 500 immunity declines, the world has been through many waves of COVID-19 pandemic, and many 501 people have experienced breakthrough infections. Those who have been both vaccinated and 502 infected with SARS-CoV-2 can produce much stronger immune response compared to those who 503 have only been vaccinated or infected. Several studies suggest that hybrid immunity confers more 504 effective cross-variant neutralization and more durable protection against new infections²⁹⁻³¹. The

505 investigational vaccine demonstrated the ability to induce a substantial humoral immune response,

506 characterized by an outstanding seroconversion rate and significant increases in neutralizing titer

507 and S-protein specific antibody from baseline.

This study also had several limitations. Firstly, data interpretation was based on a relatively small sample size and more data from ongoing phase 3 trials will provide further data to comprehensively evaluate the safety and efficacy of SW-BIC-213 as a booster shot in the heterologous boost regimen. Secondly, the study populations were not ethnically diverse, with all participants were of Asian descent. Thirdly, the neutralizing potency against currently circulating VOCs Omicron BA.4/5 was not evaluated in the present due to the constantly shifting of variants of concern, which will be addressed in the ongoing phase 3 trials.

515In conclusion, COVID-19 mRNA vaccine SW-BIC-213 manifests a favorable safety profile and 516 was highly immunogenic in all eligible subjects aged ≥ 18 years of both phase 1 and phase 2 trials, 517 suggesting potential for further investigation as a means of controlling and preventing COVID-19. 518 However, considering that COVID-19 vaccines have been widely used worldwide as primary 519 series, the majority of targeted population may already have some extent of protection, thus a 520 specific dosage of 25 µg would be set for the booster study. Moreover, with the rising number of 521 breakthrough infections of SARS-CoV-2 in previously immunized individuals, there is increasing 522 concern for the need of a booster vaccine dose to combat waning antibody levels and new variants. 523 As a result, an ongoing phase 3 study in Laos is further evaluating SW-BIC-213 as a booster 524 vaccination against the Omicron variant and other emerging VOC in healthy individuals aged 18 525 years and above, who have already completed the 2-dose series with COVID-19 inactivated 526 vaccines.

538

540 Author contributions

- 541 M Mayxay is the principal investigator of this trial. D D, C P, B Yu, J-Y Wu and Y-Z
- 542 Wang participated in designing the trial and study protocol. R-J Pei and P-P Liu
- 543 contributed to laboratory testing. P Han and M-Y Shen contributed to develop and
- 544 manufacture SW-BIC-213. Y-J Chen contributed to manuscript writing. S-K Lan, Y Li
- and B Luo participated in the site work, including the recruitment, participants' visits and
- ⁵⁴⁶ data collection. J-X Li, H-F Shen, W-X Guan and H-W Li contributed to the critical
- review and revising of the manuscript. D-W Lv, L-R Jin, F-F Zhao and C-C Xu
- 548 contributed to verify the data. All authors reviewed and approved the final version of the
- 549 manuscript.

Competing Interest Declaration

551	The authors declare no competing interests.
552	

577 Figure legends



Figure 1 Screening and Randomization of the Participants.

580 The screening and Randomization profile of phase 1 (A) and Phase 2 (B) trial.

25 μg (n=20) 31.3	45 μg (n=20)	P-value	P	lacebo	25 µg	45 µg	P-value
31.3			((n=96)	(n=191)	(n=192)	
31.3					· · ·	· · ·	
(10.3)	30.2 (10.0)	0.7337 ^[1]		46.3 (17.2)	47.5 (16.7)	47.3 (17.2)	0.8439[3]
28.5	27.0			46.5	49.0	48.0	
23.0, 38.0	23.0, 36.5			32.0, 60.0	32.0, 60.1	33.0, 60.5	
16 (80.0%)	15 (75.0%)	1.0000 ^[2]	62	2 (64.6)	92 (48.2%)	108 (56.3%)	0.0265[4]
4 (20.0%)	5 (25.0%)		34	4 (35.4)	99 (51.8%)	84 (43.8%)	
		1.0000 ^[2]					1.0000[2]
20 (100.0%)	20 (100.0%)		(1	96 00.0%)	191 (100.0%)	192 (100.0%)	
21.510 (2.337)	23.175 (3.098)	0.0624 ^[1]	2 (21.452 3.370)	21.748 (3.475)	21.283 (3.345)	0.4040[3]
21.719	22.342		2	21.076	21.406	20.953	
20.1, 23.7	21.5, 23.8			19.1, 23.5	19.5, 23.6	19.2, 23.2	
	28.5 23.0, 38.0 16 (80.0%) 4 (20.0%) 20 (100.0%) 21.510 (2.337) 21.719 20.1, 23.7	$\begin{array}{ccc} 28.5 & 27.0 \\ 23.0 & 23.0 \\ 38.0 & 36.5 \\ \hline \\ (80.0\%) & (75.0\%) \\ \hline \\ (80.0\%) & (75.0\%) \\ \hline \\ (20.0\%) & (20) \\ (100.0\%) & (20) \\ \hline \\ (100.0\%) & (20) \\ (100.0\%) \\ \hline \\ 21.510 & 23.175 \\ (2.337) & (3.098) \\ 21.719 & 22.342 \\ \hline \\ 20.1 & 21.5 \\ 23.7 & 23.8 \\ \hline \end{array}$	$\begin{array}{cccccccc} 28.5 & 27.0 \\ 23.0 & 23.0 \\ 38.0 & 36.5 \\ \end{array} \\ \begin{array}{c} 16 & 15 \\ (80.0\%) & (75.0\%) \\ \end{array} \\ \begin{array}{c} 1 \\ (80.0\%) & (75.0\%) \\ \end{array} \\ \begin{array}{c} 1 \\ (25.0\%) \\ \end{array} \\ \begin{array}{c} 1 \\ (20.0\%) \\ (25.0\%) \\ \end{array} \\ \begin{array}{c} 1 \\ (25.0\%) \\ \end{array} \\ \begin{array}{c} 1 \\ (20.0\%) \\ \end{array} \\ \begin{array}{c} 20 \\ (100.0\%) \\ \end{array} \\ \begin{array}{c} 0 \\ (100.0\%) \\ \end{array} \\ \end{array} \\ \begin{array}{c} 0 \\ (100.0\%) \\ \end{array} \\ \end{array} $ \\ \begin{array}{c} 0 \\ (100.0\%) \\ \end{array} \\ \begin{array}{c} 0 \\ (100.0\%) \\ \end{array} \\ \end{array} \\ \begin{array}{c} 0 \\ (100.0\%) \\ \end{array} \\ \begin{array}{c} 0 \\ (100.0\%) \\ \end{array} \\ \end{array} \\ \begin{array}{c} 0 \\ (100.0\%) \\ \end{array} \\ \end{array} \\ \begin{array}{c} 0 \\ (100.0\%) \\ \end{array} \\ \end{array} \\ \begin{array}{c} 0 \\ (100.0\%) \\ \end{array} \\ \end{array} \\ \begin{array}{c} 0 \\ (100.0\%) \\ \end{array} \\ \end{array} \\ \begin{array}{c} 0 \\ (100.0\%) \\ \end{array} \\ \end{array} \\ \begin{array}{c} 0 \\ (100.0\%) \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} 0 \\ (100.0\%) \\ \end{array} \\ \end{array} \\ \end{array} \\ \\ \begin{array}{c} 0 \\ (100.0\%) \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} 0 \\ (100.0\%) \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} 0 \\ (100.0\%) \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} 0 \\ (100.0\%) \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} 0 \\ (100.0\%) \\ \end{array} \\ \end{array} \\ \end{array} \\ \bigg \\	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccc} 28.5 & 27.0 & 46.5 \\ 23.0 & 23.0 & 32.0 & 60.0 \\ 38.0 & 36.5 & 60.0 \\ \hline \\ 16 & 15 & 1.0000^{[2]} & 62 (64.6) & 62 (64.6) & 62 (64.6) & 62 & 64.6 \\ \hline \\ (80.0\%) & (75.0\%) & 1.0000^{[2]} & 34 (35.4) & 62 & 64.6 & 64.6$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$

586 **Table 1. Baseline demographic characteristics of participants in phase 1 and phase 2 trials**

587 Data are mean (SD), media, or n (%). p values are calculated with ^[1]t- test, ^[2] Fisher's exact test, 588 ^[3]ANOVA or ^[4]Chi-square test. BMI=body-mass index









590 Figure 2 Vaccination-related adverse events and reactions in the phase 1 and phase 2 trials.

- 591 A. Severity of Solicited Adverse Reactions in phase 1 trial.
- 592 B. Severity of Solicited Adverse Reactions in phase 2 trial, participants were divided into two 593 age groups, 18-60 years old group (upper panel) and 60 years old above group (lower panel).
- 594 Severity of the adverse effects were classified according to the NIH guidelines. The Chi-square
- test was used to assess differences in the incidence of adverse effects among the specified groups.
- 596 The results of compared analysis among the three groups were expressed as no significant
- 597 difference (ns, P>0.5), * ($p \le 0.05$), ** ($p \le 0.01$), *** ($p \le 0.001$), **** ($p \le 0.0001$).



599 Figure 3 SW-BIC-213 induced Spike protein binding antibodies in phase 1 and phase 2 trials.

- A. Geometric mean SARS-CoV-2 spike protein binding antibodies titers determined by ELISA
 at the indicated time points (day) post vaccination in phase 1 trial.
- B. Seroconversion rates at the indicated time points (day) post vaccination in phase 1 trial.
- 603 C. Geometric mean SARS-CoV-2 spike protein binding antibodies titers determined by ELISA
 604 at the indicated time points (day) post vaccination in phase 2 trial.
- D. Seroconversion rates at the indicated time points (day) post vaccination in phase 2 trial.
- 606 Seroconversion is defined as Titer above or equal 20 in baseline-seronegative subjects or at least
- 607 4-fold rise in baseline-seropositive subjects. Statistical analysis was conducted with t test to
- 608 compare the log transformed GMTs of the indicated group. Chi-square test was used to analyze
- 609 the difference of seroconversion rate of the indicated group. The results of compared analysis were
- 610 expressed as no significant difference (ns, P>0.5), * ($p \le 0.05$), ** ($p \le 0.01$), *** ($p \le 0.001$), ****
- 611 (p≤0.0001).
- 612
- 613

medRxiv preprint doi: https://doi.org/10.1101/2023.09.11.23295344; this version posted September 12, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



616 Figure 4 SW-BIC-213 induced pseudo-virus neutralizing antibodies in phase 1 and phase 2

- 617 **trials.**
- A. GMT of SARS-CoV-2 prototype strain pseudo-virus neutralizing antibody was determined at
 the indicated time points (day) in phase 1 trial.
- B. GMT of SARS-CoV-2 delta strain pseudo-virus neutralizing antibody was determined at the
 indicated time points(day) in phase 1 trial.
- 622 C. GMT of SARS-CoV-2 omicron BA.1 strain pseudo-virus neutralizing antibody was
 623 determined at the indicated time points (day) in phase 1 trial.
- D. GMT of SARS-CoV-2 omicron BA.2 strain pseudo-virus neutralizing antibody was
 determined at the indicated time points (day) in phase 1 trial.
- E. GMT of SARS-CoV-2 prototype strain pseudo-virus neutralizing antibody was determined at
 the indicated time points (day) in phase 2 trial.
- F. GMT of SARS-CoV-2 delta strain pseudo-virus neutralizing antibody was determined at the
 indicated time points(day) in phase 2 trial.
- G. GMT of SARS-CoV-2 omicron BA.1 strain pseudo-virus neutralizing antibody was
 determined at the indicated time points (day) in phase 2 trial.
- H. GMT of SARS-CoV-2 omicron BA.2 strain pseudo-virus neutralizing antibody was
 determined at the indicated time points (day) in phase 2 trial.
- 634 Statistical analysis was conducted with t test to compare the log transformed GMTs of the indicated 635 group. The results of compared analysis were expressed as no significant difference (ns, P>0.5), *

636 $(p \le 0.05)$, ** $(p \le 0.01)$, *** $(p \le 0.001)$, **** $(p \le 0.0001)$.

- 637
- 638
- 639
- 640
- 641
- 642
- 643

- 645
- - -
- 646



Figure 5 SW-BIC-213 induced neutralizing antibodies in phase 1 and phase 2 trials.

- A. GMT of SARS-CoV-2 prototype virus neutralizing antibody determined by
 microneutralization assay in phase 1 trial.
- B. The seroconversion rate of SARS-CoV-2 prototype virus neutralizing antibody in phase 1 trial.
- 663 C. GMT of SARS-CoV-2 prototype virus neutralizing antibody determined by 664 microneutralization assay in phase 2 trial.
- D. The seroconversion rate of SARS-CoV-2 prototype virus neutralizing antibody in phase 2 trial. Seroconversion is defined as titers above or equal 4 in baseline-seronegative subjects or at least 4fold rise in baseline-seropositive subjects in phase 1 trial. Seroconversion is defined as titers above or equal 10 in baseline-seronegative subjects or at least 4-fold rise in baseline-seropositive subjects in phase 2 trial (the diversity in seroconversion definition from that of phase 2 is attributed to the difference in detection institution and detection standard). Statistical analysis was conducted with
- t test to compare the log transformed GMTs of the indicated group. Chi-square test was used to analyze the difference of seroconversion rate of the indicated group. The results of compared analysis were expressed as no significant difference (ns, P>0.5), * ($p\leq0.05$), ** ($p\leq0.01$), *** ($p\leq0.001$), **** ($p\leq0.0001$).

29

- 675
- 676

677 678

679

680

681 682

683

684

685

686 687

688



691

692 Extended Data Figure 1 SW-BIC-213 induced RBD binding antibodies in phase 1 trial.

693 A. SARS-CoV-2 RBD protein binding antibody titer determined by ELISA.

B. The seroconversion rate of SARS-CoV-2 RBD protein binding antibody.

Seroconversion is defined as Titer above or equal 20 in baseline-seronegative subjects or at least 4-fold rise in baseline-seropositive subjects. Statistical analysis was conducted with t test to compare the log transformed GMTs of the indicated group. Chi-square test was used to analyze the difference of seroconversion rate of the indicated group. The results of compared analysis were expressed as no significant difference (ns, P>0.5), * (p \leq 0.05), ** (p \leq 0.01), *** (p \leq 0.001), **** (p \leq 0.0001).

- 701
- 702
- 703
- 704
- 705
- 706
- 707
- 708
- 709



Extended Data Figure 2 Seroconversion rate of SW-BIC-213 induced pseudo-virus neutralizing antibodies in phase 1 and phase 2 trials.

- A. The seroconversion rate of SARS-CoV-2 prototype strain pseudo-virus neutralizing antibody
 at the indicated time points (day) in phase 1 trial.
- B. The seroconversion rate of SARS-CoV-2 delta strain pseudo-virus neutralizing antibody at the
 indicated time points (day) in phase 1 trial.
- C. The seroconversion rate of SARS-CoV-2 omicron BA.1 strain pseudo-virus neutralizing
 antibody at the indicated time points (day) in phase 1 trial.
- D. The seroconversion rate of SARS-CoV-2 omicron BA.2 strain pseudo-virus neutralizing
 antibody at the indicated time points (day) in phase 1 trial.
- E. The seroconversion rate of SARS-CoV-2 prototype strain pseudo-virus neutralizing antibody
 at the indicated time points (day) in phase 2 trial.
- F. The seroconversion rate of SARS-CoV-2 delta strain pseudo-virus neutralizing antibody at the
 indicated time points (day) in phase 2 trial.
- G. The seroconversion rate of SARS-CoV-2 omicron BA.1 strain pseudo-virus neutralizing
 antibody at the indicated time points (day) in phase 2 trial.
- H. The seroconversion rate of SARS-CoV-2 omicron BA.2 strain pseudo-virus neutralizing
 antibody at the indicated time points (day) in phase 2 trial.
- Seroconversion is defined as titers above or equal 10 in baseline-seronegative subjects or at least 4-fold rise in baseline-seropositive subjects. Chi-square test was used to analyze the difference of seroconversion rate of the indicated group. The results of compared analysis among the three groups were expressed as no significant difference ns (P>0.5), * ($p \le 0.05$), ** ($p \le 0.01$), *** (p
- 736 ≤0.001), **** (p≤0.0001).
- 737
- 738
- 739
- 740
- 741
- 742

743 **REFERENCES**

- 7451Cucinotta, D. & Vanelli, M. WHO Declares COVID-19 a Pandemic. Acta bio-medica : Atenei746Parmensis 91, 157-160, doi:10.23750/abm.v91i1.9397 (2020).
- 747 **2** <u>https://covid19.who.int/</u>.
- 7483Jin, Y., Hou, C., Li, Y., Zheng, K. & Wang, C. mRNA Vaccine: How to Meet the Challenge of749SARS-CoV-2. Frontiers in immunology 12, 821538, doi:10.3389/fimmu.2021.821538750(2021).
- 7514https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-752vaccines.
- 7535Angeli, F., Spanevello, A., Reboldi, G., Visca, D. & Verdecchia, P. SARS-CoV-2 vaccines:754Lights and shadows. European journal of internal medicine 88, 1-8,755doi:10.1016/j.ejim.2021.04.019 (2021).
- 7566Golob, J. L., Lugogo, N., Lauring, A. S. & Lok, A. S. SARS-CoV-2 vaccines: a triumph of757science and collaboration. JCl insight 6, doi:10.1172/jci.insight.149187 (2021).
- 758 7 Graña, C. *et al.* Efficacy and safety of COVID-19 vaccines. *The Cochrane database of* 759 *systematic reviews* **12**, Cd015477, doi:10.1002/14651858.Cd015477 (2022).
- Vira, T., Yamashita, A., Mizuki, N., Okuda, K. & Shimada, M. New vaccine production
 platforms used in developing SARS-CoV-2 vaccine candidates. *Vaccine* **39**, 197-201,
 doi:10.1016/j.vaccine.2020.11.054 (2021).
- Sharma, A., Ahmad Farouk, I. & Lal, S. K. COVID-19: A Review on the Novel Coronavirus
 Disease Evolution, Transmission, Detection, Control and Prevention. *Viruses* 13, doi:10.3390/v13020202 (2021).
- 76610Awadasseid, A., Wu, Y., Tanaka, Y. & Zhang, W. Current advances in the development of767SARS-CoV-2 vaccines. International journal of biological sciences **17**, 8-19,768doi:10.7150/ijbs.52569 (2021).
- 769
 11
 Skowronski, D. M. & De Serres, G. Safety and Efficacy of the BNT162b2 mRNA Covid-19

 770
 Vaccine. The New England journal of medicine **384**, 1576-1577,

 771
 doi:10.1056/NEJMc2036242 (2021).
- 77212Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *The New*773*England journal of medicine* **384**, 403-416, doi:10.1056/NEJMoa2035389 (2021).
- 774Gui, Y. Z. et al. Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-13 775 BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and 776 multi-arm randomised, phase 1 trial. EBioMedicine 91, 104586, 777 doi:10.1016/j.ebiom.2023.104586 (2023).
- 77814Yang, R. et al. A core-shell structured COVID-19 mRNA vaccine with favorable779biodistribution pattern and promising immunity. Signal transduction and targeted780therapy 6, 213, doi:10.1038/s41392-021-00634-z (2021).
- 781 **15** <u>https://rsc.niaid.nih.gov/clinical-research-sites/daids-adverse-event-grading-tables.</u>
- 782 **16** <u>https://www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20191231111901460.html</u>.

783	17	https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicity-
784		grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-
785		clinical.
786	18	Jackson, L. A. et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J
787		Med 383, 1920-1931, doi:10.1056/NEJMoa2022483 (2020).
788	19	Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med
789		384 , 403-416, doi:10.1056/NEJMoa2035389 (2021).
790	20	Walsh, E. E. et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine
791		Candidates. <i>N Engl J Med</i> 383 , 2439-2450, doi:10.1056/NEJMoa2027906 (2020).
792	21	Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J
793		<i>Med</i> 383 , 2603-2615, doi:10.1056/NEJMoa2034577 (2020).
794	22	Dai, L. & Gao, G. F. Viral targets for vaccines against COVID-19. Nat Rev Immunol 21, 73-
795		82, doi:10.1038/s41577-020-00480-0 (2021).
796	23	Cameroni, E. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron
797		antigenic shift. <i>Nature</i> 602 , 664-670, doi:10.1038/s41586-021-04386-2 (2022).
798	24	<sars-cov-2 and="" convalescent<="" from="" in="" neutralization="" omicron="" serum="" td="" vaccinated="" variant=""></sars-cov-2>
799		Persons.pdf>.
800	25	Liu, L. <i>et al.</i> Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2.
801		Nature 602 , 676-681, doi:10.1038/s41586-021-04388-0 (2022).
802	26	<plasma neutralization="" of="" omicron="" sars-cov-2="" the="" variant.pdf="">.</plasma>
803	27	Carreno, J. M. et al. Activity of convalescent and vaccine serum against SARS-CoV-2
804		Omicron. <i>Nature</i> 602 , 682-688, doi:10.1038/s41586-022-04399-5 (2022).
805	28	Weiss, P. & Murdoch, D. R. Clinical course and mortality risk of severe COVID-19. The
806		Lancet 395 , 1014-1015, doi:10.1016/s0140-6736(20)30633-4 (2020).
807	29	Suryawanshi, R. & Ott, M. SARS-CoV-2 hybrid immunity: silver bullet or silver lining?
808		Nature reviews. Immunology 22 , 591-592, doi:10.1038/s41577-022-00771-8 (2022).
809	30	Wang, Z. et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after
810		infection. <i>Nature</i> 595 , 426-431, doi:10.1038/s41586-021-03696-9 (2021).
811	31	Suryawanshi, R. K. et al. Limited cross-variant immunity from SARS-CoV-2 Omicron
812		without vaccination. <i>Nature</i> 607, 351-355, doi:10.1038/s41586-022-04865-0 (2022).
813		